H.I.G. BioHealth Partners, the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with over $30 billion of equity capital under management,* recently announced the sale of Vertiflex, Inc. to Boston Scientific, a global leader in medical technology, for a total equity value of approximately $465 million in cash and additional payments contingent on the Company attaining certain commercial goals.
Founded in 2005 in Carlsbad, CA, Vertiflex is a leading innovator of advanced, minimally invasive interventions for spinal stenosis and has developed and marketed the Superion® Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis.
Earl Fender, VertiFlex CEO commented, “H.I.G. was an ideal partner with which to execute on our growth strategy. Their collaborative operational approach, unique resources and deep experience helped drive the success of the Company’s commercial efforts and an outstanding outcome for all involved.”
Michael Wasserman, Ph.D., an H.I.G. Managing Director and former Vertiflex board member, said, “The successful sale to Boston Scientific is a testament to the synergy realized between investors and management to provide broad access to VertiFlex’s novel and clinically valuable products which have tremendous benefits to patients, physicians and the healthcare system as a whole. We look forward to watching the Company’s future success as they improve the quality of life for many patients suffering from LSS.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: June 24, 2019
Source: Yahoo Finance